MedTrace Logo

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

NCT03943264 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-06-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.

Conditions

  • Alzheimer Disease

Interventions

DRUG

XPro1595

XPro1595 will be delivered by subcutaneous injection once a week

Sponsors & Collaborators

Principal Investigators

  • Terrence O'Brien, MD · The Alfred

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2021-06-30
Completion
2021-09-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03943264 on ClinicalTrials.gov